CANDEL THERAPEUTICS INC (CADL) Stock Overview
USA - NASDAQ:CADL - US1374041093 - Common Stock
CADL Key Statistics, Chart & Performance
The current stock price of CADL is 6.19 USD. In the past month the price increased by 29.23%. In the past year, price increased by 2.82%.
CADL Latest News, Press Relases and Analysis
CADL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.77 | 407.19B | ||
| AMGN | AMGEN INC | 13.3 | 156.19B | ||
| GILD | GILEAD SCIENCES INC | 15.14 | 145.40B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.07 | 104.55B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 60.36B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.37 | 59.85B | ||
| ARGX | ARGENX SE - ADR | 85.97 | 48.77B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.17 | 35.16B | ||
| INSM | INSMED INC | N/A | 34.31B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.54B | ||
| NTRA | NATERA INC | N/A | 23.23B | ||
| BIIB | BIOGEN INC | 9.15 | 21.49B |
Related stock screener links
About CADL
Company Profile
Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. The company is headquartered in Needham, Massachusetts and currently employs 38 full-time employees. The company went IPO on 2021-07-27. CAN-2409 is the lead product candidate from the adenovirus platform. CAN-3110 is the lead product candidate from the herpes simplex virus (HSV) platform and is in an ongoing phase Ib clinical trial in recurrent high-grade glioma. Its enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. CAN-2409, Its advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus engineered to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s specific tumor and induce an individualized, systemic immune response against the tumor.
Company Info
CANDEL THERAPEUTICS INC
117 Kendrick Street,, Suite 450
Needham MASSACHUSETTS US
CEO: Paul Peter Tak
Employees: 38
Phone: 16179165445
CANDEL THERAPEUTICS INC / CADL FAQ
What is the stock price of CANDEL THERAPEUTICS INC today?
The current stock price of CADL is 6.19 USD. The price decreased by -5.5% in the last trading session.
What is the ticker symbol for CANDEL THERAPEUTICS INC stock?
The exchange symbol of CANDEL THERAPEUTICS INC is CADL and it is listed on the Nasdaq exchange.
On which exchange is CADL stock listed?
CADL stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CANDEL THERAPEUTICS INC stock?
12 analysts have analysed CADL and the average price target is 20.06 USD. This implies a price increase of 224.07% is expected in the next year compared to the current price of 6.19. Check the CANDEL THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CANDEL THERAPEUTICS INC worth?
CANDEL THERAPEUTICS INC (CADL) has a market capitalization of 339.83M USD. This makes CADL a Small Cap stock.
How many employees does CANDEL THERAPEUTICS INC have?
CANDEL THERAPEUTICS INC (CADL) currently has 38 employees.
What are the support and resistance levels for CANDEL THERAPEUTICS INC (CADL) stock?
CANDEL THERAPEUTICS INC (CADL) has a support level at 5.71 and a resistance level at 7.03. Check the full technical report for a detailed analysis of CADL support and resistance levels.
Should I buy CANDEL THERAPEUTICS INC (CADL) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CADL, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CADL, evaluating the profitability, health, valuation and growth aspects
- CANDEL THERAPEUTICS INC (CADL) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CANDEL THERAPEUTICS INC (CADL) Sales and EPS estimates to see what analysts future expectations are.
- CANDEL THERAPEUTICS INC (CADL) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CANDEL THERAPEUTICS INC (CADL) Insider and Institutional Ownership to learn about the owners and their transactions.
- CANDEL THERAPEUTICS INC (CADL) Stock Chart to make your own analysis
- CANDEL THERAPEUTICS INC (CADL) Latest news and press-releases to stay up to date.
Does CANDEL THERAPEUTICS INC (CADL) stock pay dividends?
CADL does not pay a dividend.
When does CANDEL THERAPEUTICS INC (CADL) report earnings?
CANDEL THERAPEUTICS INC (CADL) will report earnings on 2025-11-24.
What is the Price/Earnings (PE) ratio of CANDEL THERAPEUTICS INC (CADL)?
CANDEL THERAPEUTICS INC (CADL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.69).
What is the Short Interest ratio of CANDEL THERAPEUTICS INC (CADL) stock?
The outstanding short interest for CANDEL THERAPEUTICS INC (CADL) is 16.54% of its float. Check the ownership tab for more information on the CADL short interest.
CADL Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to CADL. When comparing the yearly performance of all stocks, CADL turns out to be only a medium performer in the overall market: it outperformed 60.08% of all stocks.
CADL Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CADL. While CADL seems to be doing ok healthwise, there are quite some concerns on its profitability.
CADL Financial Highlights
Over the last trailing twelve months CADL reported a non-GAAP Earnings per Share(EPS) of -0.69. The EPS increased by 59.27% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -20.89% | ||
| ROE | -24.54% | ||
| Debt/Equity | 0.01 |
CADL Forecast & Estimates
12 analysts have analysed CADL and the average price target is 20.06 USD. This implies a price increase of 224.07% is expected in the next year compared to the current price of 6.19.